These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28983968)

  • 1. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
    Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
    Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
    Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
    Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
    Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
    Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
    JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
    Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
    JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
    Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
    Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity.
    De Abreu RA; Lambooy LH; Ahment K; Brouwer C; Keizer-Garritsen JJ; Bokkerink JP; Trijbels FJ
    Adv Exp Med Biol; 2000; 486():271-5. PubMed ID: 11783498
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia.
    Mulla H; Buck H; Price L; Parry A; Bell G; Skinner R
    J Oncol Pharm Pract; 2016 Jun; 22(3):387-95. PubMed ID: 25837624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
    Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
    Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.